Myriad Genetics (MYGN) announced the appointment of Brian Donnelly as CCO, effective May 1, 2025. Prior to joining Myriad Genetics, Donnelly held senior commercial and general management roles at leading organizations such as Ancestry, Amazon, and Illumina.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $20 from $24 at Scotiabank
- Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges
- Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler
- Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley
- Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler